The role of xanthine oxidase in thiopurine metabolism: A case report

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 845-848

  Wong, Dennis R ^a   Derijks, Luc J J ^b   Den Dulk, Meyno O ^c   Gemmeke, Edy H K M ^c   Hooymans, Piet M ^a  

^a Sittard Geleen Heerlen   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c St Jans Gasthuis Hospital   (Netherlands)

Author keywords

6 mercaptopurine; Allopurinol; Azathioprine; Patient compliance; Xanthine oxidase

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AMINOTRANSFERASE; AZATHIOPRINE; LIVER ENZYME; MERCAPTOPURINE; PREDNISOLONE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE;

ADULT; ARTICLE; AUTOIMMUNE PANCREATITIS; BIOTRANSFORMATION; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ERYTHROCYTE; FEMALE; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; WEIGHT REDUCTION;

6-MERCAPTOPURINE; AZATHIOPRINE; FEMALE; HUMANS; MIDDLE AGED; PANCREATITIS, CHRONIC; XANTHINE OXIDASE;

EID: 36549053255     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815bf4dc     Document Type: Article

References (17)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
2. Derijks LJJ, Gilissen LPL, Engels LGJB, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit. 2004;26:311-318.
3. Dubinsky MC, Lamothe S, Hui YY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
4. Ecklund BI, Moberg M, Bergquist J, et al. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol. 2006;70:747-754.
5. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther. 2000;14:1009-1014.
6. Nyhan WL. The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J Inherit Metab Dis. 1997;20:171-178.
7. Puig JG, Mateos FA, Torres RJ, et al. Purine metabolism in Lesch-Nyhan syndrome versus Kelley-Seegmiller syndrome. J Inherit Metab Dis. 1994;17:138-142.
8. Pritsos CA. Cellular distribution, metabolism, and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000;129:195-208.
9. Aklillu E, Carillo JA, Makonnen E, et al. Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol. 2003;59:533-536.
10. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 1991;50:663-672.
11. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992;52:643-658.
12. Saruwatari J, Nakagawa K, Shindo J, et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther. 2002;72:200-208.
13. Zimm S, Collins JM, O'Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983;34:810-817.
14. Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet. 1993;342:83-84.
15. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother. 1996;30:951-954.
16. Venkat Raman V, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med. 1990;228:69-71.
17. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005;22:1161-1162.